Professor Michael Barry:

The Senator is talking about the timeline between 6 June and 5 August when the relevant company put in a pricing and reimbursement application. It has nothing to do with me. I have no hand, act or part in that. All I can do is take ownership of what we have done. When we were asked to look at it on 5 August, we finished on 14 August. Where is that now? It is a very high-cost drug and has a significant budget impact. There is no question about that. So we asked for more information from the company that is very happy to provide it and I understand that the information will be with us in a month or so. When we receive the information I can assure the Senator that it will receive our full attention and will be done as quickly as possible. It will be done properly but it will be done quickly.